Based on the ratio R (ALT/ULN)/(ALP/ULN), ChILI can manifest in a cholestatic pattern (frequently associated with monotherapy using anti-PD-L1 inhibitors), hepatocellular (more prevalent in combination therapies involving anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitors and correlating with hepatitis severity), and mixed presentations. This evidence concerns the gene GPT and hepatitis A virus infection.